Boan Biotech (06955): Phase III clinical trial of BA1104 (navulizumab) completed in China and reached the main end point

Zhitongcaijing · 1d ago

Zhitong Finance App News, Boan Biotech (06955) announced that the phase III clinical trial of the company's PD-1 inhibitor BA1104 (navulizumab injection) in China has been completed and reached the main end point. The company will soon submit a marketing license application for this product to the China National Drug Administration (NMPA). BA1104 is the first Odivo® (Opdivo®) biosimilar in China to complete phase III clinical trials. According to the “Technical Guidelines for Biosimilar Similarity Evaluation and Indication Extraction”, it is proposed to apply for Odivo® approved indications in China.

Navulizumab is a humanized monoclonal antibody (IgG4 subtype) against the programmed cell death 1 (PD-1) receptor. It enhances the anti-tumor response of T cells by blocking the binding of PD-1 receptors to their ligands PD-L1 and PD-L2, and is a cornerstone drug for tumor immunotherapy. According to public information, Odivo® has been approved for multiple indications in dozens of countries and regions around the world, covering multiple tumor types, and clinical applications span all stages of tumor treatment, including new adjuvant treatment before surgery, adjuvant treatment after surgery, first-line and post-line treatment for advanced tumors, etc. Uses include single drugs, combined chemotherapy, and combined use with new immune checkpoint inhibitors. In 2025, Odivo®'s global sales revenue reached US$10.049 billion, an increase of 8% over the previous year.

BA1104 was developed in accordance with biosimilar research guidelines in China, the United States, Europe, and Japan. This phase III clinical trial is a randomized, double-blind, multicenter clinical study to compare the efficacy and safety of BA1104 and Odivo® in combination with chemotherapy in patients with advanced or metastatic esophageal squamous cell carcinoma, respectively.

The phase III clinical study reached the predetermined main end point. The study results showed that the confidence interval between BA1104 and the reference drug completely fell within the preset equivalent limit of objective response rate (ORR) ratios, proving the equivalence between the two. The independent center's imaging evaluation results are in good agreement with the researchers' evaluation results. Secondary efficacy endpoints include disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). The results of the two groups were highly similar, and no clinically significant differences in efficacy were observed. In terms of safety, BA1104 has good overall safety and tolerability, and the two are highly similar in terms of safety. Both groups of drug-resistant antibodies (ADA) and neutralizing antibodies (NAb) had low and similar positive rates, indicating that the immunogenicity of the two groups was similar.

Previously, BA1104 had completed pharmacological and non-clinical comparison studies with Odivo®, and a randomized, double-blind, single-dose phase I clinical study was conducted in healthy Chinese male volunteers to evaluate the pharmacokinetic (PK) characteristics, safety, and immunogenicity of the two. The 90% confidence interval between BA1104 and the reference drug AUC0-∞, AUC0-t, and Cmax all fell within the preset range of 80.00%-125.00%, confirming that the PK characteristics of the two are highly similar. The findings have been published in the international journal BioDrugs. In the phase I clinical study, the positive rate of Ada and NaB was similar, and the immunogenicity was similar.

In addition to China, the company is also actively expanding the overseas layout of BA1104. Previously, the company had already completed communication with the US Food and Drug Administration (FDA) at the Biological Product Development (BPD) 2b meeting. The FDA agreed on a “simplified” clinical development strategy. It only requires carrying out a PK similarity test (phase I trial) to submit a biological product license application (BLA), and there is no need to carry out phase III clinical trials. In addition, the company also plans to register and list BA1104 in more countries and regions.

PD-1 inhibitors are currently the cornerstone drugs used in the field of tumor immunotherapy. In addition to developing BA1104 biosimilar drugs, the company is also actively exploring its therapeutic potential in combination with its own innovative antibodies. The company uses “tumor immunity+antibody conjugate drugs (IO+ADC)” as the development strategy to build a differentiated innovative pipeline to explore innovative solutions that balance efficacy and safety and respond more effectively to drug resistance, with a view to promoting new breakthroughs in tumor treatment.